<clinical_study>
<study_id>
<org_name>
  Novo_Nordisk
</org_name>
<org_full_name>
  Novo Nordisk
</org_full_name>
<org_study_id>
  NN304-1613
</org_study_id>
<nct_id>
  NCT00184600
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
</textblock>
</brief_title>
<acronym>
  4T
</acronym>
<official_title>
<textblock>
  3 Year Efficacy and Safety Comparison of Adding Insulin Detemir, Biphasic Insulin Aspart 30 or Insulin Aspart to Oral Antidiabetic Drug Treatment in Type 2 Diabetes.
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Novo Nordisk
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Public Access to Clinical Trials
</name_title>
<organization>
  Novo Nordisk A/S
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  Ireland: Irish Medicines Board
</regulatory_authority>
<regulatory_authority>
  United Kingdom: Medicines and Healthcare Products Regulatory Agency
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  This trial is conducted in Europe.
  The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD treatment in type 2 diabetes and to verify the safety of use ( number and severity of episodes of hypoglycaemia, body weight and side effects).
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
 Completed 
</status>
<date>
2009-09 
</date>
</status_block>
<start_date>
<date>
  2004-11
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
2009-08 
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
2009-08 
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  3
</number_of_arms>
<primary_outcome>
<measure>
  Proportion of subjects who achieve HbA1c = 6.5% without hypoglycaemia
</measure>
<time_frame>
  in the last 4 weeks of year 1/year 3
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Efficacy and durability of the insulin regimens
</measure>
<time_frame>
  over a 12-36 months following a treatment algorithm
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Adverse events
</measure>
<time_frame>
  during treatment
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  body weight
</measure>
<time_frame>
  after 52 or 156 weeks of treatment
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Quality of Life
</measure>
<time_frame>
  after 52 or 156 weeks of treatment
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Blood glucose
</measure>
<time_frame>
  after 52 or 156 weeks of treatment
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Hypoglycaemia
</measure>
<time_frame>
  during treatment
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
707 
</enrollment>
<condition>
  Diabetes Mellitus, Type 2
</condition>
<arm_group>
<arm_group_label>
  A
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  B
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  C
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  biphasic insulin aspart
</primary_name>
<description>
<textblock>
  Treat-to-target, s.c. injection, twice daily plus option for insulin aspart
</textblock>
</description>
<arm_group_label>
  B
</arm_group_label>
<other_name>
  BIasp
</other_name>
<other_name>
  NovoMix 30
</other_name>
<other_name>
  NovoLog Mix 70/30
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  insulin detemir
</primary_name>
<description>
<textblock>
  Treat-to-target, s.c. injection, once or twice daily plus option for insulin aspart
</textblock>
</description>
<arm_group_label>
  A
</arm_group_label>
<other_name>
  NN304
</other_name>
<other_name>
  Levemir
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  insulin aspart
</primary_name>
<description>
<textblock>
  Treat-to-target, s.c. injection, twice daily plus option for insulin detemir
</textblock>
</description>
<arm_group_label>
  C
</arm_group_label>
<other_name>
  ANA
</other_name>
<other_name>
  NovoRapid
</other_name>
<other_name>
  NovoLog
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Type 2 Diabetes
    - Insulin naive
    - On OAD treatment
    - BMI = 40.0 kg/m2
    - HbA1c7.0%-10% (both inclusive)
  Exclusion Criteria:
    - Proliferative retinopathy
    - Recurrent major hypoglycaemia
    - Cardial problems
    - Uncontrolled hypertension
    - Impaired hepatic or renal function
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Jens Larsen, MD
</name>
<affiliation>
<agency>
  Novo Nordisk A/S
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Public Access to Clinical Trials - Novo Nordisk
</name>
<phone>
  Please Contact NN via email
</phone>
<phone_ext>
</phone_ext>
<email>
  clinicaltrials@novonordisk.com
</email>
</contact>
<location>
<facility>
<name>
</name>
<address>
<city>
  Dublin
</city>
<state>
</state>
<zip>
</zip>
<country>
  Ireland
</country>
</address>
</facility>
<status>
 Completed 
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Oxford
</city>
<state>
</state>
<zip>
</zip>
<country>
  United Kingdom
</country>
</address>
</facility>
<status>
 Completed 
</status>
</location>
<see_also>
<annotation>
<textblock>
  Clinical Trials at Novo Nordisk
</textblock>
</annotation>
<url>
  http://novonordisk-trials.com
</url>
</see_also>
<initial_release_date>
  2005-09-13
</initial_release_date>
<last_release_date>
2009-09-02 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
